IngenioRx, UC’s new pharmacy benefit plan manager, to begin on May 1
On May 1, 2019, IngenioRx (an Anthem company) will replace ExpressScripts as the pharmacy benefit plan manager for UC medical plan members
On May 1, 2019, IngenioRx (an Anthem company) will replace ExpressScripts as the pharmacy benefit plan manager for UC medical plan members. This transition will provide UC medical plan members with 24/7/365 customer service access along with improved online services and information.
There are no changes to UC medical or pharmacy plans as a result of this change and plan members can continue to use the same retail pharmacies used today for pharmacy purchases. Individuals currently taking advantage of home delivery or who use specialty medications will receive additional communications directly from Anthem in the coming weeks.
Additional information is available on the Anthem Medical Plan Options page.
Questions?
Plan members with questions are welcome to contact Anthem at the phone number on their ID card.
Have additional questions? Reach out to the UC Benefits team at benefits@uc.edu or call 513-556-6381.
Related Stories
UC faculty and staff among Rising Star leadership honorees
January 5, 2026
Two UC faculty and staff members are among this year's Rising Star leadership program sponsored by YWCA Greater Cincinnati. Kelli Beecher, assistant professor in the UC College of Nursing, and Brittany Bibb, assistant director of programs and operations in the UC Division of Student Affairs, are among the emerging leaders of 2026. They were featured in the publication Movers & Makers.
What's behind the mysterious rise of migraines?
January 5, 2026
Weather patterns such as extreme heat and storm conditions have been linked to migraine attacks, and research shows those environmental conditions are becoming more common. As National Geographic recently reported, one of the leading theories behind this mysterious rise is that climate change may be playing a role.
Top six 2025 nephrology drug approvals
January 5, 2026
“2025 has been a landmark year for kidney disease therapeutics, marked by a comprehensive slate of FDA approvals covering endothelin-receptor blockade, complement inhibition, GLP-1-based metabolic protection, and B-cell-directed therapy,” Prakash Gudsoorkar, MD, associate professor of clinical medicine at the University of Cincinnati College of Medicine and staff nephrologist at UC Health, recently told MedCentral.